Due to their favorable impact on spleen volume and disease-related symptoms, as well as potential survival benefits, JAK2 inhibitors such as ruxolitinib will likely remain a mainstay in the treatment of patients with MPN [27–33]. Here, JAK2 is linked to myeloproliferative disorder.